This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • An Open-Label Extension Study of DS-5565 for 52 We...
Clinical trial

An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fribromyalgia

Read time: 1 mins
Last updated:4th Sep 2014

This is an open-label study of DS-5565 in subjects who either completed participation in a preceding Phase 3 study of DS-5565 in fibromyalgia (FM); i.e. DS5565-A-E309, DS5565-A-E310, or DS5565-A-E311 or are de novo subjects. Eligible subjects will be assigned to receive open-label DS-5565 for 52 weeks. All subjects will receive DS-5565 15 mg once daily (QD) for the first three weeks of the treatment period. After three weeks, subjects may be titrated to 15 mg twice daily (BID) based on protocol-specified criteria.

Category Value
Study start date 2014-09-04

View full details